1. At a Glance – Welcome to the Pharma Circus 🎪
Ladies and gentlemen, welcome to the financial IPL where Shukra Pharmaceuticals just smashed a ₹20 Cr quarterly profit… on just ₹39 Cr revenue. Yes, you read that right — margins so fat they could qualify for a government subsidy.
But wait… this isn’t Sun Pharma. This isn’t even a midcap pharma darling. This is a ₹1,398 Cr microcap with ₹63 Cr annual revenue doing ₹20 Cr quarterly profit like it just discovered the philosopher’s stone.
So what’s going on here?
Is this:
- A hidden gem quietly compounding?
- A pharma outsourcing wizard?
- Or a company that found the cheat code to accounting?
Because when a company shows 69% operating margin, your brain should not say “wow” — it should say:
“Bhai, kya chal raha hai?”
Let’s open the forensic file.
2. Introduction – Pharma Company or Financial Magician?
Shukra Pharmaceuticals isn’t new. It’s been around since 1993 — quietly manufacturing formulations, doing lab testing, and occasionally waking up investors with sudden spikes.
But here’s the twist.
For years, this company was basically:
- Small revenue
- Low visibility
- Almost ignored
Then suddenly:
- Revenue jumps
- Profit explodes
- Margins go crazy
- Stock becomes a multibagger
And now?
It’s sitting at:
- P/E: 48
- Price to Book: 21x
- OPM: 55%+
For a company doing trading + manufacturing mix.
That’s like a roadside dosa stall suddenly reporting margins higher than Apple.
So the real question is:
👉 Is this a turnaround story… or a temporary spike dressed as a business model?
3. Business Model – WTF Do They Even Do?
Let’s simplify this.
Shukra Pharma has three main revenue streams:
1. Trading (58%)
Yes, more than half the business is trading pharma products.
Basically:
